Health
Researchers develop ultrapotent miniproteins that target SARS-CoV-2 receptor-binding domain – News-Medical.Net
Researchers have investigated the effectiveness of a bioengineered miniprotein in protecting against SARS-CoV-2 infection in vivo. The researchers evaluated the…
Last September, researchers at the University of Washington, USA, reported the development of computer-designed small proteins – ‘miniproteins’ – that can target the receptor-binding domain (RBD) on the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic.
This work was published in the journal Science, claiming the lead antiviral miniprotein candidate, named LCB1, which exhibited better protective…
-
Noosa News8 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News9 hours agoMotorcyclist dies in crash with truck
-
Noosa News23 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General23 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate